Kevin Schichlein was staring at a paradox: patients with chronic lung diseases like COPD, asthma, and cystic fibrosis almost always had low vitamin D levels, and those with the lowest levels fared worst—but giving them vitamin D pills did nothing to help. "We think the reason is that oral vitamin D gets inactivated by an enzyme in the lung's blood vessels before it ever reaches airway tissue," said Schichlein, a postdoctoral fellow at the UNC School of Medicine’s Marsico Lung Institute. His insight, co-authored with Dr. Ilona Jaspers and Dr. M. Bradley Drummond and published in the Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation, could reshape how we treat millions struggling with respiratory illness. For years, clinical trials have poured resources into oral vitamin D supplementation, only to find no meaningful improvement in lung function, flare-ups, hospitalizations, or quality of life—despite successfully raising blood levels of the vitamin. The missing link? Delivery.
The problem may not be the vitamin itself, but the path it takes. When swallowed, vitamin D travels through the liver and into the bloodstream, but researchers believe an enzyme in the lung’s vascular lining deactivates it before it can reach the airway tissues where it’s needed. This explains the baffling gap between strong observational data—showing clear links between deficiency and poor outcomes—and the failure of oral supplements to deliver results. In cystic fibrosis patients, low vitamin D correlates with worse respiratory function; in COPD, it’s tied to higher hospitalization rates; in asthma, to reduced lung capacity. Yet pills haven’t moved the needle.
The solution, the team argues, lies in bypassing the bloodstream entirely. Inhaled vitamin D could deliver the nutrient directly to the lungs, maximizing local effect while minimizing systemic exposure. Early studies in upper airway diseases have already shown promise in preclinical models and preliminary human trials, suggesting that localized delivery can activate immune defenses and reduce inflammation where it matters most. "Topical or inhaled delivery of vitamin D is already being explored for upper airway diseases," noted Jaspers, a professor of pediatrics and environmental sciences, "moving to the lower airways could be a logical extension of these observations."
This shift in strategy could unlock new therapeutic pathways for conditions that affect over 500 million people worldwide. The authors emphasize that clinical trials are urgently needed to test safety, optimal dosing, and efficacy. But the potential is clear: by rethinking how we deliver a well-known nutrient, we might finally harness its full power. "There has been a longstanding disconnect between the established harms of vitamin D deficiency and the failure of clinical trials," said Drummond, a pulmonologist and professor of medicine. "We believe this disconnect may reflect a suboptimal delivery method... Direct inhaled delivery could unlock new therapeutic opportunities."
If future studies confirm its promise, inhaled vitamin D might become a quiet revolution in respiratory care—transforming a failed supplement into a targeted, life-improving therapy.